Dexcom has obtained European approval for the latest generation of its wearable diabetes sensor, the G7 continuous glucose monitor, for adults and children ages two and up. Designed to be 60% smaller ...
DexCom (NasdaqGS:DXCM) has begun a broad U.S. rollout of its G7 15-day continuous glucose monitoring system, extending sensor wear time for users. The company is preparing a nationwide release of ...
LONDON--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
Dexcom is in seventh heaven: A year after its initial FDA submission, the diabetes tech maker has finally gotten the green light to begin rolling out its latest continuous glucose monitor system in ...
The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...
People with Type 1 diabetes are estimated to make up to 180 more decisions a day than someone without the disease, according to a study from Stanford University. Each meal, workout, or night’s sleep ...
DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results